HUP0102067A2 - A TNF receptorcsaládba tartozó érett FLINT (mFLINT) polipeptid vagy más néven az OPG3 terápiás alkalmazásai - Google Patents

A TNF receptorcsaládba tartozó érett FLINT (mFLINT) polipeptid vagy más néven az OPG3 terápiás alkalmazásai

Info

Publication number
HUP0102067A2
HUP0102067A2 HU0102067A HUP0102067A HUP0102067A2 HU P0102067 A2 HUP0102067 A2 HU P0102067A2 HU 0102067 A HU0102067 A HU 0102067A HU P0102067 A HUP0102067 A HU P0102067A HU P0102067 A2 HUP0102067 A2 HU P0102067A2
Authority
HU
Hungary
Prior art keywords
mflint
flint
opg3
polypeptides
fasl
Prior art date
Application number
HU0102067A
Other languages
English (en)
Inventor
Thomas Frank Bumol
Shenshen Dou
Andrew Lawrence Glasebrook
Kenneth Elliot Gould
John Edward Hale
Josef Georg Heuer
Kwan Yuk Hui
Alexei Kharitonenkov
Jacques Mizrahi
Songqing Na
Timothy Wayne Noblitt
Charles Arthur Reidy
Ho Yeong Song
Jian Wang
Xiying Wu
Steven Harold Zuckerman
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP0102067A2 publication Critical patent/HUP0102067A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Az érett FLINT (mFLINT) a FasL-hez és a LIGHT-hoz kötődik, és a FasL-Fas kölcsönhatást megakadályozza. Az mFLINT a FasL-Fas általközvetített apoptotikus és proinflammatorikus aktivitást gátolja, ésaz abnormális apoptózissal és gyulladással járó betegségek kezelésébenhasznos. A találmány a FLINT és az mFLINT készítmény nukleotidszekvenciáját biztosítja. Az mFLINT-et expresszáló transzgenikusállatok létrehozását és jellemzését közzéteszi. Az mFLINTalkalmazásával terápiás összetételeket és kezelési eljárásokat isbiztosít. Ó
HU0102067A 1998-03-30 1999-03-30 A TNF receptorcsaládba tartozó érett FLINT (mFLINT) polipeptid vagy más néven az OPG3 terápiás alkalmazásai HUP0102067A2 (hu)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US7985698P 1998-03-30 1998-03-30
US8607498P 1998-05-20 1998-05-20
US9964398P 1998-09-09 1998-09-09
US11257798P 1998-12-17 1998-12-17
US11293398P 1998-12-18 1998-12-18
US11270398P 1998-12-18 1998-12-18
US11340798P 1998-12-22 1998-12-22
PCT/US1999/006797 WO1999050413A2 (en) 1998-03-30 1999-03-30 THERAPEUTIC APPLICATIONS OF MATURE FLINT (mFLINT) POLYPEPTIDES OR OPG3, A MEMBER OF THE TNF RECEPTOR SUPERFAMILY

Publications (1)

Publication Number Publication Date
HUP0102067A2 true HUP0102067A2 (hu) 2001-10-28

Family

ID=27568394

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102067A HUP0102067A2 (hu) 1998-03-30 1999-03-30 A TNF receptorcsaládba tartozó érett FLINT (mFLINT) polipeptid vagy más néven az OPG3 terápiás alkalmazásai

Country Status (16)

Country Link
US (1) US20040167074A1 (hu)
JP (1) JP2002512006A (hu)
KR (1) KR20010042364A (hu)
CN (1) CN1303429A (hu)
AU (1) AU3369199A (hu)
BR (1) BR9909328A (hu)
CA (1) CA2324517A1 (hu)
CZ (1) CZ20003433A3 (hu)
EA (1) EA200001004A1 (hu)
HU (1) HUP0102067A2 (hu)
ID (1) ID27820A (hu)
IL (1) IL138626A0 (hu)
NO (1) NO20004873L (hu)
PL (1) PL343847A1 (hu)
TR (1) TR200002824T2 (hu)
WO (1) WO1999050413A2 (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2277925A1 (en) 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6.alpha. and 6.beta.
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
DE69839401T2 (de) 1997-09-18 2009-05-07 Genentech Inc., San Francisco Dcr3 polypeptid, ein tnfr homolog
WO2000037094A2 (en) * 1998-12-22 2000-06-29 Eli Lilly And Company Therapeutic applications of flint polypeptides
AU3739500A (en) * 1999-03-30 2000-10-16 Eli Lilly And Company Protease resistant flint analogs
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
AU783682B2 (en) 1999-08-04 2005-11-24 Amgen, Inc. Fhm, a novel member of the TNF ligand supergene family
AU6517800A (en) 1999-08-04 2001-03-05 Amgen, Inc. Ntr3, a member of the tnf-receptor supergene family
AU7053000A (en) * 1999-09-10 2001-04-10 Eli Lilly And Company Flint compounds and formulations thereof
EP1225908A2 (en) * 1999-10-20 2002-07-31 Eli Lilly And Company Therapeutic applications of flint polypeptides
AU1915201A (en) * 1999-12-07 2001-06-18 Eli Lilly And Company Improving stability of flint through o-linked glycosylation
WO2002018622A2 (en) * 2000-08-25 2002-03-07 Human Genome Sciences, Inc. TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
WO2002066050A1 (fr) * 2001-02-23 2002-08-29 Takeda Chemical Industries, Ltd. Inhibiteurs de caspase 3
ATE438662T1 (de) 2003-03-26 2009-08-15 Apogenix Gmbh Verbesserte fc-fusionsproteine
WO2006072137A1 (en) * 2005-01-07 2006-07-13 Northern Sydney And Central Coast Area Health Service Treatment for autoimmune and inflammatory conditions
WO2008080623A2 (en) 2006-12-28 2008-07-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Neutralization of cd95 activity blocks invasion of glioblastoma cells in vivo
JP5665739B2 (ja) * 2008-07-14 2015-02-04 ドイチェス クレープスフォルシュングスツェントルムＤｅｕｔｓｃｈｅｓ Ｋｒｅｂｓｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ 炎症性疾患を治療するためのｃｄ９５インヒビターの使用
CN102671186B (zh) * 2011-09-19 2014-08-06 上海市肿瘤研究所 促造血的药物组合物及其应用
SI2874659T1 (sl) 2012-07-18 2016-11-30 Apogenix Ag Inhibitorji signalizirane poti CD95 za zdravljenje MDS
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
EP3395355A4 (en) 2015-12-18 2019-06-12 Talengen International Limited METHOD FOR PREVENTING AND TREATING CERVICAL EROSION
WO2017101873A1 (zh) * 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗放射性和化学性损伤的方法
WO2020205662A1 (en) 2019-03-29 2020-10-08 Myst Therapeutics, Inc. Ex vivo methods for producing a t cell therapeutic and related compositions and methods
US20230032934A1 (en) 2019-11-27 2023-02-02 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
WO2021174208A1 (en) 2020-02-27 2021-09-02 Myst Therapeutics, Llc Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2277925A1 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6.alpha. and 6.beta.
US5885800A (en) * 1997-02-04 1999-03-23 Smithkline Beecham Corporation DNA encoding tumor necrosis related receptor, TR4
AU9013998A (en) * 1997-07-21 1999-02-10 Zymogenetics Inc. Tumor necrosis factor receptor ztnfr-5
JP2001512667A (ja) * 1997-08-06 2001-08-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトオーファンレセプターｎｔｒ−１
DE69839401T2 (de) * 1997-09-18 2009-05-07 Genentech Inc., San Francisco Dcr3 polypeptid, ein tnfr homolog
WO1999026977A1 (en) * 1997-11-24 1999-06-03 Biogen, Inc. Novel receptors opg-2

Also Published As

Publication number Publication date
KR20010042364A (ko) 2001-05-25
WO1999050413A3 (en) 1999-12-02
US20040167074A1 (en) 2004-08-26
EA200001004A1 (ru) 2001-06-25
AU3369199A (en) 1999-10-18
NO20004873D0 (no) 2000-09-28
TR200002824T2 (tr) 2000-12-21
CZ20003433A3 (cs) 2001-10-17
BR9909328A (pt) 2000-12-12
PL343847A1 (en) 2001-09-10
ID27820A (id) 2001-04-26
JP2002512006A (ja) 2002-04-23
IL138626A0 (en) 2001-10-31
WO1999050413A2 (en) 1999-10-07
CN1303429A (zh) 2001-07-11
CA2324517A1 (en) 1999-10-07
NO20004873L (no) 2000-11-24

Similar Documents

Publication Publication Date Title
HUP0102067A2 (hu) A TNF receptorcsaládba tartozó érett FLINT (mFLINT) polipeptid vagy más néven az OPG3 terápiás alkalmazásai
HK1077518A1 (en) Peptides that modulate nerve growth factor (ngf) activity, their compositions and use
FR14C0051I2 (fr) Dialkylfumarates pour le traitement de maladies autoimmunes
DK0689449T3 (da) Præparater til anvendelse i humanterapi, kendetegnet ved kombination af et muramylpeptid med en cytokin
DE69132306T2 (de) Menschlicher und Murin-Interleukin-5-Rezeptor
IS5405A (is) Prostaglandín gerandefni og notkun þeirra til að meðhöndla beintruflanir
EE200100372A (et) TWEAK-valgu ja TWEAK-valgu retseptori antagonistid ja nende kasutamine immuunhaiguste raviks
BR9711130A (pt) Genes npr para a resistência adquirida e usos dos mesmos.
DE69728323D1 (de) Variante des humanen C3a Rezeptors; diagnostische und therapeutische Verwendungen
DE69738613D1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
ID20600A (id) Sel-sel yang dimodifikasi secara genetik dan penggunaannya dalam profilaksis atau terapi penyakit
DE69228997D1 (de) Menschliche il-3-varianten
BRPI0415290A (pt) uso terapêutico de variantes de quimiocina
NO970264L (no) Farmasöytiske blandinger omfattende et chimærisk TNF-bindende protein
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
DK1185293T3 (da) IL6RIL6-kimær til behandling af neurodegenerative sygdomme
KR100915291B1 (ko) 쑥뜸기
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
DK1012286T3 (da) Allelvariant af humant STAT3
WO2000037094A3 (en) Therapeutic applications of flint polypeptides
IL154777A0 (en) Il-6 receptor/il-6 chimera in huntington's disease
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner
O'connell Role of Fas–FasL in inflammatory diseases
MX9801550A (es) Uso de muteinas de citocinas de tipo silvestre como inmunogenos.
DE997146T1 (de) Medikament zur behandlung der diabetischen nierenkrankheit und zur verspätung der niereninsuffizienz